ERBB2 and breast cancer: As a result, HER2– LAMP vaccine produced tumor regression in 30% of vaccinated mice with an endogenous model of metastatic HER2+ BC, by enhanced major histocompatibility complex (MHC) class I and II presentation that elevated levels of antigen-specific polyfunctional CD8+ T cells (Chen et al., 2020).